Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
Peter S GrimisonAntony MersiadesAdrienne KirbyAnnette TognelaIan N OlverRachael Lisa MortonPaul HaberAnna WalshYvonne LeeEhtesham AbdiStephen Della-FiorentinaMorteza AghmeshehPeter FoxKaren BriscoeJasotha SanmugarajahGavin MarxGanessan KichenadasseHelen WheelerMatthew ChanJenny ShannonCraig GedyeStephen D BegbieR John SimesMartin R StocklerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
THC:CBD is an effective adjunct for chemotherapy-induced nausea and vomiting despite standard antiemetic prophylaxis, but was associated with additional adverse events. Drug availability, cultural attitudes, legal status, and preferences may affect implementation. Future analyses will evaluate the cost-effectiveness of THC:CBD.
Keyphrases
- chemotherapy induced
- phase ii
- placebo controlled
- clinical trial
- double blind
- open label
- phase iii
- primary care
- study protocol
- healthcare
- current status
- oxidative stress
- mental health
- phase ii study
- quality improvement
- randomized controlled trial
- squamous cell carcinoma
- adverse drug
- drug induced
- emergency department
- rectal cancer